HMGB1 and pancreatic neoplasm: Studies have shown that HMGB1 activates RAGE to affect the NF-κB signaling pathway by reducing p65 phosphorylation levels, promoting pancreatic cancer metastasis, and inducing chemoresistance to gemcitabine (91).